Is neglect of self-clearance biasing TB vaccine impact estimates?
exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India
research
Impact TB vaccination for PLHIV
Modelling to inform PPCs for TB VX for PLHIV
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: A scoping review
This paper synthesizes the insights and lessons learned from different vaccine introductions among adult populations in LMICs from the last decade (i.e., 2013 to 2023).
Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study
modelling the population-level health and economic impacts of introducing Vaccae vaccination to inform policy-makers in China
The full value of vaccine assessments concept—current opportunities and recommendations
Building on the success of the recent applications of the FVVA framework, we see important new opportunities to maximize the future utility of FVVAs to country and global stakeholders and provide a proof-of-concept for analyses in other areas of disease control and prevention.
Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report
A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.
Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.
TbVacMod; Estimating the epidemiologic impact of new TB vaccines in high-burden settings
This is an NIH-funded study which will estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. We are developing model scenarios based on input from country stakeholders, including national TB program and immunization program officials.
Meeting the 2030 End TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio.
From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.
Estimating the epidemiologic impact of new TB vaccines in the U.S.
This is a study funded by the American Lung Association which will explore the potential impact of targeted implementation of a prevention of disease vaccine in a low TB burden country, the U.S.A.